The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Nucleos(t)ide analog therapy blocks DNA synthesis by the hepatitis B virus (HBV) reverse transcriptase and can control the infection, but treatment is life-long and has high costs and unpredictable long-term side effects. The profound suppression of HBV by the nucleos(t)ide analogs and their ability to cure some patients indicates that they can push HBV to the brink of extinction. Consequently, more patients could be cured by suppressing HBV replication further using a new drug in combination with the nucleos(t)ide analogs. The HBV ribonuclease H (RNAseH) is a logical drug target because it is the second of only two viral enzymes that are essential for viral replication, but it has not been exploited, primarily because it is very difficult to produce active enzyme. To address this difficulty, we expressed HBV genotype D and H RNAseHs in E. coli and enriched the enzymes by nickel-affinity chromatography. HBV RNAseH activity in the enriched lysates was characterized in preparation for drug screening. Twenty-one candidate HBV RNAseH inhibitors were identified using chemical structure-activity analyses based on inhibitors of the HIV RNAseH and integrase. Twelve anti-RNAseH and anti-integrase compounds inhibited the HBV RNAseH at 10 µM, the best compounds had low micromolar IC(50) values against the RNAseH, and one compound inhibited HBV replication in tissue culture at 10 µM. Recombinant HBV genotype D RNAseH was more sensitive to inhibition than genotype H. This study demonstrates that recombinant HBV RNAseH suitable for low-throughput antiviral drug screening has been produced. The high percentage of compounds developed against the HIV RNAseH and integrase that were active against the HBV RNAseH indicates that the extensive drug design efforts against these HIV enzymes can guide anti-HBV RNAseH drug discovery. Finally, differential inhibition of HBV genotype D and H RNAseHs indicates that viral genetic variability will be a factor during drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905 · cited 2×
“Despite these limitations, the ability of protracted nucleos(t)ide analog therapy to slowly suppress cccDNA and HBsAg and to cure a small minority of HBV patients [10–13,21–23] indicates that the nucleos(t)ide analogs can push the virus to the brink of elimination.”
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810 · cited 1×
“coli RNAseH I and II [30], DNA transposases including the Tn5 transposase [31], retroviral integrases including the HIV integrase [32], the RuvC Holliday junction resolvase [33], the Argonaute RNAse [34], and human RNAseH 1 and 2 [35,36].”
Nowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620
Control of cccDNA function in hepatitis B virus infection
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., & Dandri, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.022 · Cited by 552 · cited 1×
“The key form of the HBV genome in cells that must be eliminated to clear the infection is the nuclear episomal covalentlyclosed circular DNA (cccDNA) that is the template for transcription of all HBV RNAs [19].”
Three-dimensional structure of ribonuclease H from E. coli
Katayanagi, K., Miyagawa, M., Matsushima, M., Ishikawa, M., Kanaya, S., Ikehara, M., Matsuzaki, T., & Morikawa, K. (1990) · Nature · doi:10.1038/347306a0 · Cited by 349
Nowotny, M., & Yang, W. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601076 · Cited by 250 · cited 1×
“The RNAseH mechanism is believed to involve both divalent cations [29,38,39], although a one-ion mechanism has also been proposed [40,41].”
Recombining the structures of HIV integrase, RuvC and RNase H
Yang, W., & Steitz, T. A. (1995) · Structure · doi:10.1016/s0969-2126(01)00142-3 · Cited by 246
Chung, S., Himmel, D. M., Jiang, J.-K., Wojtak, K., Bauman, J. D., Rausch, J. W., Wilson, J. A., Beutler, J. A., Thomas, C. J., Arnold, E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000757 · Cited by 80 · cited 6×
“the divalent cations in the active site [64,65,69,70,73,76].”
Influential
Cited by
Present and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Menéndez-Arias, L., Sebastián-Martín, A., & Álvarez, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.12.019 · Cited by 123
Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.178 · Cited by 54
Vörös, J., Urbanek, A., Rautureau, G. J. P., O'Connor, M., Fisher, H. C., Ashcroft, A. E., & Ferguson, N. (2014) · Journal of Virology · doi:10.1128/jvi.02575-13 · Cited by 27
“cations preserve reported RH catalytic residues (62) but eliminate”
Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold
(2022) · doi:10.1002/pro.4421 · Cited by 22
Metadata
- Authors
- Tavis, J. E., Cheng, X., Hu, Y., Totten, M., Cao, F., Michailidis, E., Aurora, R., Meyers, M. J., Jacobsen, E. J., Parniak, M. A., & Sarafianos, S. G.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-22
- Volume
- 9
- Issue
- 1
- Pages
- e1003125
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2045108297
- Cited by
- 106
- References
- 8
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.